来凯医药-b(02105)涨超4%,截至发稿,涨4.69%,报10.26港元,成交额3539.45万港元。消息面上,来凯医药近日宣布,其自主研发的LAE102(ActRIIA单克隆抗体)针对超重/肥胖在中国开展的I期临床试验取得重大进展:单剂量递增研究(SAD研究)已成功完成。SAD研究共招募了64名健康受试者,平均BMI23.2±2.2kg/m2,包括5个静脉给药队列和3个皮下给药队列。SAD...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.